Semaglutide is best known as a weekly injection, but an oral (pill) version exists too. It is easy to assume “oral” and “injectable” are simply two delivery methods for the same approved use. They are not, and that distinction matters for anyone comparing this page to our injectable semaglutide page.

Two different oral products, two different approvals

There are two oral semaglutide products worth knowing apart:

• Rybelsus is the first FDA-approved oral semaglutide tablet. Its approval is for type 2 diabetes, not weight loss. A provider prescribing it for weight loss is prescribing off-label, meaning outside the condition the FDA approved it for.
• Oral Wegovy is a separate, more recently approved oral formulation that does carry its own FDA approval for chronic weight management, distinct from Rybelsus’s diabetes-only approval.

This is different from the injectable side, where Wegovy (injectable) has long carried a direct weight-management approval. On the oral side, only the oral Wegovy pill carries that same weight-management approval; Rybelsus does not. Treating “oral semaglutide” as one undifferentiated category would blur that distinction, so we don’t.

There are also compounded oral formulations, such as sublingual drops or dissolvable tablets, made by a compounding pharmacy to an individual prescription. These are not FDA-approved products themselves. A Heally provider can explain what that means for you in plain terms if a compounded option comes up during your evaluation.

Who a Heally provider evaluates this for

Miracle Leaf® refers interested patients to Heally rather than performing this evaluation itself. A Heally provider reviews your health history and goals, discusses which oral option (if any) fits, and explains the approval basis and off-label status where it applies, before anything is prescribed. If an injectable option makes more sense for you, they can discuss that too, and our injectable semaglutide and tirzepatide pages cover those paths in more depth.

What to expect

Oral semaglutide is typically taken daily rather than weekly, on an empty stomach with a small amount of water, and food or other medication needs to wait a set amount of time afterward per the product’s label, an administration routine that’s meaningfully different from a once-weekly injection. Side effects overlap heavily with the injectable form: nausea, diarrhea, and other gastrointestinal symptoms are the most commonly reported, especially early on. If cost or route of administration is the deciding factor for you, our metformin page covers a lower-cost, non-injectable, non-GLP-1 option some providers use instead of or alongside a GLP-1 medication.

Sources

• FDA-approved label, Wegovy (semaglutide) injection, NDA 215256, June 2021 (accessdata.fda.gov), for the weight-management approval baseline referenced above
• Public product descriptions, Heally (getheally.com/patients/semaglutide), pulled 2026-07-23, for how Heally itself describes its oral and injectable semaglutide offerings

Medically reviewed by REVIEW LATER - named medical reviewer pending. Last reviewed 2026-07-23.